ResearcherInstitut d'Investigació Biomédica de BellvitgeActive in the last 2 years
Juan Fabregat
Matched on OpenAlex author ID A5107853950. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 5
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 3
- The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma. Last author DOI 10.1016/j.suronc.2023.102027↗
- Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospect… Last author DOI 10.1097/md.0000000000032126↗
- Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. First author DOI 10.1016/j.ciresp.2017.07.008↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Berta Laquente · 3 shared papers, 2017–2024 · strength 0.46
- Paper The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pa… DOI 10.1016/j.suronc.2023.102027↗
- Paper Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients… DOI 10.1097/md.0000000000032126↗
- Paper Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. DOI 10.1016/j.ciresp.2017.07.008↗
- Lluís Secanella · 3 shared papers, 2017–2024 · strength 0.46
- Paper The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pa… DOI 10.1016/j.suronc.2023.102027↗
- Paper Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients… DOI 10.1097/md.0000000000032126↗
- Paper Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. DOI 10.1016/j.ciresp.2017.07.008↗
- Juli Busquets · 3 shared papers, 2017–2024 · strength 0.46
- Paper The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pa… DOI 10.1016/j.suronc.2023.102027↗
- Paper Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients… DOI 10.1097/md.0000000000032126↗
- Paper Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. DOI 10.1016/j.ciresp.2017.07.008↗
- Helena Verdaguer · 1 shared paper, 2017 · strength 0.06
- Emilio Ramos · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.